According to a new study, regular physical exercise for 6 months can reduce the daily inhaled corticosteroids (ICS) dose without compromising asthma control. The results of this study were published in the Journal of allergy and clinical immunology.

150 ICS-treated symptomatic asthma patients were randomly assigned to either an exercise intervention group, who exercised three times a week for 6 months or a control group who continued their usual lifestyle. The primary outcome was the proportion who had a 25% or greater reduction in ICS dose at 6 months. Secondary outcome of this study was actual ICS dose (in micrograms) per day.

63% in the exercise group achieved the primary outcome compared to 50% in the control group at the 6-month visit. Additionally, the daily ICS dose decreased in favor of the exercise group with a mean difference of -234 μg, a 24% reduction from baseline.

Based on the above findings, this study showed that regular physical exercise for 6 months is safe, well tolerated and can reduce the daily ICS dose without compromising asthma control.

According to a recent study, the combination of doxycycline and azithromycin given intravenously is an effective treatment option to treat severe scrub typhus. This study was published in, The New England Journal of Medicine.

This was a multicenter, double-blind, randomized, controlled trial which included 794 patients who were 15 years of age or older with severe scrub typhus and showing either respiratory, hepatic, cardiovascular, renal, or neurologic complications. The patients were given doxycycline, azithromycin, or both (combination therapy) intravenously for a period of 7 days. The primary outcome of the study was a composite of death from any cause on day 28, persistent complications on day 7, and persistent fever on day 5.

It was observed that the patients who were treated with combination therapy resulted in a lower incidence of the composite primary outcome (33%) compared with treating with doxycycline (47%) or azithromycin (48%) alone. The composite of death and other adverse effects on day 28 were similar in the three groups.

Hence it can be suggested that combination therapy with doxycycline and azithromycin is beneficial to treat severe scrub typhus.

According to a recent study, the combination of doxycycline and azithromycin given intravenously is an effective treatment option to treat severe scrub typhus. This study was published in, The New England Journal of Medicine.

This was a multicenter, double-blind, randomized, controlled trial which included 794 patients who were 15 years of age or older with severe scrub typhus and showing either respiratory, hepatic, cardiovascular, renal, or neurologic complications. The patients were given doxycycline, azithromycin, or both (combination therapy) intravenously for a period of 7 days. The primary outcome of the study was a composite of death from any cause on day 28, persistent complications on day 7, and persistent fever on day 5.

It was observed that the patients who were treated with combination therapy resulted in a lower incidence of the composite primary outcome (33%) compared with treating with doxycycline (47%) or azithromycin (48%) alone. The composite of death and other adverse effects on day 28 were similar in the three groups.

Hence it can be suggested that combination therapy with doxycycline and azithromycin is beneficial to treat severe scrub typhus.

A latest study reported that doxycycline is safe, inexpensive and reduces the need for ICU admission when added to SoC in covid-19 patients. This study was published in the Journal, PLos One.

This randomized, controlled, open labelled, parallel group study included 387 patients aged 40-90 years were randomised to receive treatment with SoC plus doxycycline or SoC only. The primary outcome was the need for ICU admission as judged by the attending physicians.

Doxycycline was associated with a relative risk reduction (RRR) and absolute risk reduction (ARR) were Intent to treat 31.6% RRR, 7.4% ARR, Per protocol  40.7% RRR, 9.6% ARR, As treated 43.2% RRR, 10.8% ARR.

Based on the results of the study, it can be concluded that doxycycline reduces the need for ICU admission when added to SoC.